


1/9

**Figure 1: 1<sup>st</sup> generation of production clones of TNFRII-Fc and TNFRII-Fc-IL1ra chimera: 24-well plate expression in serum-free medium**



2/9

**Figure 2: Affinity purification of chimeric TNFRII-Fc-II-1ra**


**Non-reduced**

**Reduced**

BEST AVAILABLE COPY


3/9

**Figure 3: An example of our troubleshooting capability: reducing a degradation problem for chimeric TNFRII-Fc-IL-1ra by altering the first purification step: HPLC analysis of intact and partially degraded chimeric TNFRII-Fc-IL-1ra with TNFRII-Fc control.**




4/9


Figure 4: SEC-HPLC analysis of TNFRII-FC-IL-1ra after formulation and lyophilization




5/9



6/9




7/9



8/9

Figure 8: Cell-based TNF alpha neutralization test





9/9

Figure 9: Cell-based IL-1 neutralization test

